Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Fineqia Launches World’s First ETN Deploying Underlying Assets in DeFi (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
IMV Inc
IMVIF
Healthcare
Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:IMVIF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(1)
•••
Jthom376
X
Comment by
Jthom376
on Jan 16, 2023 8:50am
RE:RE:I/O 360 feb23
Re. DLBCL data...assume it's solid but not amazing. Good enough to continue justifying. Not good enough to have lasting change in SP.... probably cause a pop allowing for ATM release. Assumption
...more
(38)
•••
Normandt
X
Post by
Normandt
on Jan 13, 2023 9:13am
Data
Of the 17 treated patients, 5 showed response 2 Complete (CR), 3 Partial Responses (PR) (RECIST v1.1) This is fantastic.
(2)
•••
europe10
X
Comment by
europe10
on Jan 11, 2023 2:51pm
RE:I/O 360 feb23
Never mind who is there to listen It is all about results release DLBCL If it is as good as IMV wants us to think....
(3)
•••
antigua1987
X
Post by
antigua1987
on Jan 11, 2023 1:28pm
I/O 360 feb23
full throttle 4 day IO event feb 7-10 @nyc. some weak hands just read that CSO Jeremy holds the floor on final day, 3pm for 20mins...the very last scheduled speaker/session over the 4 days. Will
...more
(3)
•••
antigua1987
X
Post by
antigua1987
on Jan 11, 2023 8:51am
new TCR report - jan10/23 - anyone?
not a tcr subscriber, however, anyone who is, pls provide this probable shill's latest view on imvs tapdancing
(2)
•••
europe10
X
Post by
europe10
on Jan 09, 2023 8:45am
update a Sunday?
Strange, Update on a Sunday The inevitable very dilutive financing came in even worse than I feared Half of the company given away Any advantages? Only if Wainwright decides to take it for a run. 65 $
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Jan 08, 2023 5:01pm
New Press Release - IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S
Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023Recently strengthened financial position with the completion of a $9M...
read article.
(38)
•••
Normandt
X
Post by
Normandt
on Dec 22, 2022 1:00pm
Imv institutional ownership
https://images.fintel.io/us-imv-so.png
(38)
•••
Normandt
X
Post by
Normandt
on Dec 21, 2022 10:04am
Target price
Analyst (4) Price target Average 63.13 $ Current 2.90 Average 63.13
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 20, 2022 12:39pm
New Press Release - IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today the closing of its previously...
read article.
(10)
•••
prosciutto
X
Post by
prosciutto
on Dec 16, 2022 12:29pm
$10/share
https://mailchi.mp/7d4557411e31/data-less-lymphoma-release-sparks-rush-of-trading?e=804db9ee01
(38)
•••
Normandt
X
Post by
Normandt
on Dec 16, 2022 10:21am
Complete responses
Complete responses.....this is something big. A buyout is possible anytime. GLTA
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 16, 2022 9:11am
IMV ...... P.O announced....what else eh!!!!!
There is a reason for all that volume and price action yesterday. Looks like Mr. Maggot is really getting creative in ways to disguise his method to lay everyone out with high priced paper. JMHO You
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 16, 2022 8:04am
New Press Release - IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today that it has entered into definitive...
read article.
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 15, 2022 2:33pm
IMV ....wow!!!!!!!!!!
Boom
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
A Canadian Company Focused on Exploring and Developing Saskatchewan’s Diamond Resources
Have you held units of a TD mutual fund, other than through a discount broker? Learn more.
The world's largest undeveloped diamond deposit is trading at a discount